(4S,6S)-4-(2,4-difluoro-5-(4-(trifluoromethyl)pyridin-3-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine | 1616100-45-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (4S,6S)-4-(2,4-difluoro-5-(4-(trifluoromethyl)pyridin-3-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine
• 英文别名: (4S,6S)-4-[2,4-difluoro-5-[4-(trifluoromethyl)pyridin-3-yl]phenyl]-6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine
• CAS: 1616100-45-8
• 化学式: C₂₂H₁₉F₅N₄OS
• 分子量: 482.477
• InChiKey: MIDNKGZIKNKERZ-RXVVDRJESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  33
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• [EN] 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION<br/>[FR] 4,6-DIARYLAMINOTHIAZINES À TITRE D'INHIBITEURS DE BACE1 ET LEUR UTILISATION POUR RÉDUIRE LA PRODUCTION DES BÊTA-AMYLOÏDES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014098831A1

  公开（公告）日：2014-06-26

  Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen or C1-C3 alkyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, -C=OC1-4 alkyl, -S02C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is -NHCO-, or is a single bond; and L and Z together can be absent.

  化合物的结构式（I），包括其药用盐，如下所示：（I），其中R1和R2分别是氢或-CH3；或者R1和R2可以通过添加-(CH2)4-在环中连接在一起；R3是氢或C1-C3烷基；Y和Z分别是C6-C10芳基或5-10成员杂环基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4二烷基氨基、卤代C1-4烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基、-C=OC1-4烷基、-S02C1-4烷基和C2-C4炔基的0-3取代基取代；A选自苯基、苄基、噁唑基、噻唑基、异噁唑基、咪唑基、吡唑基、吡啶基、嘧啶基和吡嗪基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4二烷基氨基、卤代C1-4烷基、羟基C1-6烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基和C2-C4炔基的0-3取代基取代；L为-NHCO-，或者是单键；而L和Z可以缺失。
• 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150329506A1

  公开（公告）日：2015-11-19

  Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R 1 and R 2 are independently hydrogen, or —CH 3 ; or R 1 and R 2 can join together in a ring by adding —(CH 2 ) 4 —; R 3 is hydrogen or C 1 -C 3 alkyl; Y and Z are independently a C 6 -C 10 -aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C 1-4 alkylamino, C 1-4 dialkylamino, haloC 1-4 alkyl, CN, C 1 -C 6 alkyl or cycloalkyl, C 1 -C 6 alkoxy, —C═OC 1-4 alkyl, —SO 2 C 1-4 alkyl, and C 2 -C 4 alkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C 1-4 alkylamino, C 1-4 dialkylamino, haloC 1-4 alkyl, hydroxyC 1-6 alkyl, CN, C 1 -C 6 alkyl or cycloalkyl, C 1 -C 6 alkoxy, and C 2 -C 4 alkynyl; L is —NHCO—, or is a single bond; and L and Z together can be absent.

  本文列出了公式（I）的化合物，包括其中的药物可接受的盐：（I）其中R1和R2分别为氢或-CH3；或R1和R2可以通过添加-(CH2)4-形成环；R3为氢或C1-C3烷基；Y和Z分别为C6-C10芳基或5-10成员的杂环基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4双烷基氨基、卤C1-4烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基、-C═OC1-4烷基、-SO2C1-4烷基和C2-C4炔基的0-3个取代基进行取代；A选自苯基、苄基、噁唑基、噻唑基、异噁唑基、咪唑基、吡唑基、吡啶基、嘧啶基和吡嗪基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4双烷基氨基、卤C1-4烷基、羟基C1-6烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基和C2-C4炔基的0-3个取代基进行取代；L为-NHCO-或单键；L和Z可以一起不存在。
• US9475784B2
  申请人：——

  公开号：US9475784B2

  公开（公告）日：2016-10-25